Paclitaxel-Coated Balloon Angioplasty For Treatment Research Articles

IP133. Early Experience With Paclitaxel-Coated Balloon Angioplasty for Treatment of Autogenous Hemodialysis Fistula Outflow Stenosis

IP133. Early Experience With Paclitaxel-Coated Balloon Angioplasty for Treatment of Autogenous Hemodialysis Fistula Outflow Stenosis

TCT-588 Cost-effectiveness of paclitaxel-coated balloon angioplasty for treatment of coronary restenosis in bare-metal stents

In-stent restenosis (ISR) is a persistent problem limiting the long-term success of percutaneous coronary intervention. Recent studies have demonstrated safety and efficacy of drug-eluting balloon (DEB) angioplasty for the treatment of coronary ISR. The cost-effectiveness of this practice is unknown

A Randomized, Multicenter, Single-Blinded Trial Comparing Paclitaxel-Coated Balloon Angioplasty With Plain Balloon Angioplasty in Drug-Eluting Stent Restenosis: The PEPCAD-DES Study

This study sought to define the impact of paclitaxel-coated balloon angioplasty for treatment of drug-eluting stent restenosis compared with uncoated balloon angioplasty alone. Drug-coated balloon angioplasty is associated with favorable results for treatment of bare-metal stent restenosis. In this prospective, single-blind, multicenter, randomized trial, the authors randomly assigned 110 patients with drug-eluting stent restenoses located in a native coronary artery to paclitaxel-coated balloon angioplasty or uncoated balloon angioplasty. Dual antiplatelet therapy was prescribed for 6 months. Angiographic follow-up was scheduled at 6 months. The primary endpoint was late lumen loss. The secondary clinical endpoint was a composite of cardiac death, myocardial infarction attributed to the target vessel, or target lesion revascularization. There was no difference in patient baseline characteristics or procedural results. Angiographic follow-up rate was 91%. Treatment with paclitaxel-coated balloon was superior to balloon angioplasty alone with a late loss of 0.43 ± 0.61 mm versus 1.03 ± 0.77 mm (p < 0.001), respectively. Restenosis rate was significantly reduced from 58.1% to 17.2% (p < 0.001), and the composite clinical endpoint was significantly reduced from 50.0% to 16.7% (p < 0.001), respectively. Paclitaxel-coated balloon angioplasty is superior to balloon angioplasty alone for treatment of drug-eluting stent restenosis. (PEPCAD DES-Treatment of DES-In-Stent Restenosis With SeQuent® Please Paclitaxel Eluting PTCA Catheter [PEPCAD-DES]; NCT00998439).